News & events

News & events
<picture><source type="image/webp" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/18e05/Image.webp 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/81bef/Image.webp 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/2d0b8/Image.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/bbd3f/Image.jpg 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/087e6/Image.jpg 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg 2960w" alt="&lt;p&gt;Image of a middle aged man dressed in a blazer, clapping his hands while smiling.&lt;/p&gt;
"/></picture>

News
18 November 2022Latest
Mendus AB: Report from the Extraordinary General Meeting of Mendus AB (publ) on 18 November 2022
At the Extraordinary General Meeting (the “EGM”) of Mendus AB (publ), reg. no 556629-1786, (the “Company”) on 18 November 2022 the EGM adopted, inter alia, the following resolution. For more detailed...
Learn more
16 November 2022
Mendus AB: Mendus to host key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission
Virtual webinar to take place Wednesday, November 30, 2022 @ 1 PM ET / 7PM CET  Upcoming data from Phase 2 ADVANCE II trial of DCP-001 at ASH in December 2022    Mendus AB (“Mendus” publ; IMMU.ST, or...
Learn more
11 November 2022
Mendus AB: Mendus AB (publ) Interim Report July – September 2022
“In Q3 of 2022, we brought Mendus in a strong position to reach its upcoming milestones. We have been preparing for presentation of the updated survival results from our ADVANCE II Phase 2 trial,...
Learn more
10 November 2022
Mendus AB: Mendus announces Nomination Committee for the 2023 Annual General Meeting
Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee have been appointed in accordance with the principles for appointment of the Nomination Committee, adopted by the...
Learn more
8 November 2022
Mendus AB: Mendus to present data at SITC 2022 demonstrating the potential of the DCOne platform to expand memory NK cells for therapeutic purposes
STIMULATION WITH DCONE CELLS LEADS TO SELECTIVE AND STRONG >200-FOLD MEDIAN EXPANSION OF MEMORY NK CELLS  Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies...
Learn more
3 November 2022
Mendus AB: Mendus to present multiple abstracts at ASH 2022 including an oral presentation of updated AML survival results from the Phase 2 ADVANCE II trial
Mendus AB (“Mendus” publ; IMMU.ST, or “the Company”), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that updated results from the Company’s...
Learn more
1 November 2022
Mendus AB: Mendus to participate in upcoming conferences in November
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and...
Learn more

Events
10 December 2022
Upcoming
64th American Society of Hematology Annual MeetingUpdated results from the Phase 2 ADVANCE II clinical trial will be presented in an oral presentation on December 12. In addition, the company will present immunomonitoring data in a separate poster presentation on December 10.  
Learn more
November 2022Upcoming
Key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission
Mendus will host a key opinion leader (KOL) webinar highlighting the current state of maintenance treatment and immunotherapy in acute myeloid leukemia (AML) patients. The event will feature two leading clinical experts, Assoc. Prof. Dr. Amer Zeidan, MBBS, MHS, from the Yale School of Medicine, and Prof. Dr. med. Uwe Platzbecker, from the Leipzig University Hospital.
Learn more
November 2022Previous
Redeye Life Science Day
CEO Erik Manting will participate. A pre-recorded company presentation will be made available by the conference organizer prior to the event.
Learn more
November 2022Previous
Jefferies Healthcare Conference
CEO Erik Manting will participate.
Learn more

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi-1002417752-4PLL7sQCtrB3jgaKQzHJXh:before { opacity: 1; background-image: url('/static/755e562542c233156a7bec1f19e2a86b/afb86/new-events-mobile.png'); }

InvestorsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
Investors

News

Mendus AB: Report from the Extraordinary General Meeting of Mendus AB (publ) on 18 November 2022

Mendus AB: Mendus to host key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission

Mendus AB: Mendus AB (publ) Interim Report July – September 2022

Mendus AB: Mendus announces Nomination Committee for the 2023 Annual General Meeting

Mendus AB: Mendus to present data at SITC 2022 demonstrating the potential of the DCOne platform to expand memory NK cells for therapeutic purposes

Mendus AB: Mendus to present multiple abstracts at ASH 2022 including an oral presentation of updated AML survival results from the Phase 2 ADVANCE II trial

Mendus AB: Mendus to participate in upcoming conferences in November

Events

64th American Society of Hematology Annual Meeting

Key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission

Redeye Life Science Day

Jefferies Healthcare Conference

Investors

Keep up to date